GMAB vs DBVT

Genmab A/S (GMAB) offers the better valuation at 14.

5x trailing P/E (23. 7x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Genmab A/S (GMAB) delivered a total return of -24.

9%, compared to -69. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: GMAB returned +85. 7% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Genmab A/S (GMAB) is the lower-risk stock at 0.

94β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 34% more volatile than GMAB relative to the S&P 500. On balance sheet safety, Genmab A/S (GMAB) carries a lower debt/equity ratio of 3% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Genmab A/S grew EPS 83.

9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 36.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31. 1% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — GMAB leads at 95. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 137.

7% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Genmab A/S (GMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94)). Both have compounded well over 10 years (GMAB: +85. 7%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GMAB is a mid-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.